Literature DB >> 3937059

The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.

J R Fozard, M Zreika, M Robin, M G Palfreyman.   

Abstract

The pharmacological properties of two selective inhibitors of monoamine oxidase (MAO) type B, L-deprenyl and MDL 72145 [(E)-2-(3,4-dimethoxyphenyl)-3-fluoroallylamine, HCl], have been investigated in rats and mice in relation to their effects on MAO. Selective inhibition of MAO B achieved following 18 h pretreatment with L-deprenyl and/or MDL 72145 did not per se lead to prominent pharmacological activity; no effects were seen in the mouse "Behavioural Despair" test, hypothermia induced by reserpine in mice was neither prevented nor reversed and there was no change in the cardiovascular responsiveness of the pithed rat to tyramine, noradrenaline or stimulation of the spinal sympathetic outflow. L-Deprenyl differed from MDL 72145 in that short term treatment with this drug caused positive effects in the "Behavioural Despair" test, reversal of reserpine hypothermia, indirect sympathomimetic stimulation of blood pressure and heart rate in the pithed rat and ipsilateral rotation in rats with unilateral nigro-striatal lesions. Qualitatively similar effects were seen with dexamphetamine. The marked difference between the pharmacological effects of MDL 72145 and L-deprenyl despite equivalent inhibition of MAO B suggests that many of the pharmacological actions of L-deprenyl result from its amphetamine-like sympathomimetic properties. MDL 72145 can, therefore, be considered a more reliable tool with which to explore the functional importance of MAO B inhibition in experimental animals and man.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3937059     DOI: 10.1007/bf00634237

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  29 in total

Review 1.  Neuronal monoamine oxidase: specific enzyme types and their rates of formation.

Authors:  N H Neff; C Goridis
Journal:  Adv Biochem Psychopharmacol       Date:  1972

2.  A method of stimulating the complete sympathetic outflow from the spinal cord to blood vessels in the pithed rat.

Authors:  J S Gillespie; T C Muir
Journal:  Br J Pharmacol Chemother       Date:  1967-05

3.  (E)-2-(3,4-dimethoxyphenyl)-3-fluoroallylamine: a selective, enzyme-activated inhibitor of type B monoamine oxidase.

Authors:  P Bey; J Fozard; J M Lacoste; I A McDonald; M Zreika; M G Palfreyman
Journal:  J Med Chem       Date:  1984-01       Impact factor: 7.446

4.  (-)Deprenyl in the treatment of Parkinson's disease.

Authors:  W Birkmayer; P Riederer; M B Youdim
Journal:  Clin Neuropharmacol       Date:  1982       Impact factor: 1.592

5.  Monoamine oxidase of types A and B in the saphenous vein and mesenteric artery of the dog.

Authors:  M M Caramona
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-05       Impact factor: 3.000

6.  Potentiation by deprenil of 1-dopa induced circling in nigral-lesioned rats.

Authors:  R E Heikkila; F S Cabbat; L Manzino; R C Duvoisin
Journal:  Pharmacol Biochem Behav       Date:  1981-07       Impact factor: 3.533

7.  Effects of L-deprenyl on human growth hormone secretion.

Authors:  M Koulu; R Lammintausta
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

8.  Depression of sympathetic nervous function by DL-alpha-monofluoromethyldopa, an enzyme-activated, irreversible inhibitor of L-aromatic amino acid decarboxylase.

Authors:  J R Fozard; M Spedding; M G Palfreyman; J Wagner; J Möhring; J Koch-Weser
Journal:  J Cardiovasc Pharmacol       Date:  1980       Impact factor: 3.105

9.  The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.

Authors:  J D Elsworth; M Sandler; A J Lees; C Ward; G M Stern
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

10.  Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.

Authors:  F Karoum; L W Chuang; T Eisler; D B Calne; M R Liebowitz; F M Quitkin; D F Klein; R J Wyatt
Journal:  Neurology       Date:  1982-05       Impact factor: 9.910

View more
  2 in total

1.  The influence of amine metabolizing enzymes on the pharmacology of tyramine in the isolated perfused mesenteric arterial bed of the rat.

Authors:  J Elliott; B A Callingham; D F Sharman
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

2.  Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.

Authors:  A Churchyard; C J Mathias; P Boonkongchuen; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-08       Impact factor: 10.154

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.